Objective: Long-term data regarding the safety and durability of thoracic endovascular aortic repair (TEVAR) are limited. The study objective was to evaluate the long-term outcomes of TEVAR in high-risk patients with descending thoracic aortic pathology.
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Questions Society for Vascular Surgery Phone: 800-258-7188; education@vascularsociety.org aneurysm-related, 35 (74%) of which were endovascular procedures. Thirty of these were to correct endoleaks at a median of 1.4 years (interquartile range, 0.2-5.0 years). The early benefit of TEVAR is well accepted, although long-term outcomes, particularly for device-related compilations and late rupture, remain unknown. As with endovascular repair of abdominal aortic aneurysm (AAA), long-term concerns related to device integrity and late risk of rupture challenge whether these potential long-term complications will outweigh the short-term benefits of TEVAR. 8, 9 Current long-term data >5 years are limited 10, 11 and are primarily from pivotal trial results 5, 12 and population-based analyses. 1, 13 Reported aneurysmrelated mortality is heavily influenced by early events, with few to no late ruptures. Endoleak rates, however, are not insignificant at up to 19% at 5 years, 5,10,14 although they tend to decrease over time. Reported aneurysmrelated reinterventions are 3% to 8% at 5 years, many of which are to address endoleaks. The question remains whether these complications will increase long-term, outweighing the early perioperative benefit. Decisions regarding the treatment of aneurysmal disease are ultimately made by weighing the risks of treatment, both early and late, vs that of rupture. Detailed long-term data, particularly related to late rupture risk and device-related complications are necessary to make informed clinical decisions, educate patients, and understand the need for long-term surveillance. Therefore, the objective of this study was to evaluate the long-term outcomes of TEVAR in high-risk patients with descending thoracic aortic pathology.
Conclusions

METHODS
The Cleveland Clinic Institutional Review Board approved and monitored this study. Written informed consent obtained from all patients.
Patients. Under the guidance of a physician-sponsored, investigational device exemption trial (ClinicalTrials.gov Identifier: NCT00583817), 200 patients underwent TEVAR between February 2001 and January 2011 at the Cleveland Clinic, accounting for w19% of the 1058 TEVAR devices implanted at our institution during a similar period (Fig 1) . Patients were treated for thoracic aneurysm $5 cm or history of rapid growth, aneurysmal degeneration of chronic dissection, or subclavian aneurysm >2.5 cm. All patients were considered to be high-risk for conventional open surgical repair of their aortic disease and had a life expectancy of at least 2 years as estimated by the operating and consulting physicians. Complete inclusion criteria and procedural details have been published previously. 15 Of note, anatomic criteria required >10 mm proximal and distal length with diameter of #40 mm. All patients underwent implantation of Zenith TX1 or TX2 stent grafts (Cook Medical, Bloomington, Ind). There were 16 patients who received devices with a proximal scallop, 6 with distal scallop, and 2 with both. As described previously, notable changes occurred in the device design during the course of the trial. 15, 16 These included subtle changes to the delivery system or device construction, such as diameter-reducing ties and changes in device length. Eighteen patients enrolled on a compassionate use/emergency basis. The analysis excluded eight patients treated for rupture.
Imaging analysis and definitions. All images were evaluated with three-dimensional analysis tools using centerline of flow calculations, multiplanar reconstructions, and surface-rendering algorithms by research personnel trained and dedicated to reviewing all imaging related to this trial. In later years, these personnel were formally absorbed by the Cleveland Clinic Vascular Surgery Core Laboratory and functioned under its guidance.
Device migration was defined as >10-mm migration in the cranial or caudal direction compared with baseline imaging. 17 Aneurysm growth was defined as an increase in aneurysm size >5 mm and was serially assessed on follow-up axial computed tomography (CT) scans compared with baseline imaging. Of note, if a secondary intervention was performed, the scan after this intervention was used as the new baseline scan for comparison going forward. Otherwise all other definitions were based on Society for Vascular Surgery reporting standards for thoracic endovascular repair. 18 Thoracic aortic aneurysm (TAA)-related mortality was defined as any death attributable to the index TAA procedure and also any deaths related to the subsequent reintervention or complication associated with the original aortic disease pathology. TAA-related reinterventions included any procedure performed related to the initial repair or treated disease, including any procedures to treat the proximal or distal sealing zone.
Follow-up and data analysis. All patients underwent CT scanning and two-plane chest x-ray before discharge, at 1, 6, 12, and 24 months, and yearly or every other year thereafter as dictated by the operating surgeons' clinical preference. Data were collected in an Oracle Clinical database (Oracle Corp, Redwood Shores, Calif) for compliance and edit tracking purposes. Mortality data were collected from annual phone contact and clinic visits, supplemented by the Social Security Death Index and obituary searches when patients could not be reached. Follow-up was 4.8 6 3.3 years (median, 4.7 years), with 958 patient-years available for analysis. Follow-up was >5 years in 47%, >7.1 years in 25%, and >9.3 years in 10%.
Survival and freedom from events were estimated nonparametrically by the Kaplan-Meier method. The log-rank test was performed to determine differences between pathology. A Cox proportional hazard model was built to identify risk factors for mortality. A resampling validation with backwards step-down variable deletion was performed with criterion of P ¼ .05 for retention of variables in the model.
Factors included in the multivariable analysis for mortality were preoperative patient characteristics, including gender, age, history of hypertension, myocardial infarction, arrhythmia, coronary artery bypass grafting, chronic obstructive pulmonary disease, home oxygen, diabetes, dialysis, connective tissue disease, and anatomic and surgical variables, including maximum aortic diameter, pathology, number of components, and surgical modifications to the neck.
Continuous variables are reported as means and standard deviations or as median and interquartile range (IQR). Pairwise comparisons were made with t-tests or by using the Wilcoxon rank sum test. Categoric data are summarized by frequencies and percentages. When the frequency was less than five, comparisons were made using c 2 and Fisher exact tests. Statistical analysis was performed with R software (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
A total of 200 patients (46% female) were treated with Zenith TX1 or TX2 TEVAR devices (Table I ). The median age was 70 years, and a high proportion had significant cardiopulmonary disease and smoking history. Treatment was for thoracic aneurysm in 171, aneurysmal Recommendation:
ARTICLE HIGHLIGHTS
The authors suggest that thoracic endovascular aortic repair using Zenith TX1 and TX2 is durable and is associated with an acceptable incidence of reintervention and late mortality.
degeneration of chronic dissection in 28, and aortobronchial fistula in 1 (Table II) . One patient within the thoracic aneurysm group also had an associated subclavian artery aneurysm. Maximum aortic diameter was 65.6 6 14.2 mm, and an average of 1.8 TEVAR components were used (median, 2.0; IQR, 1-2). The subset of chronic dissection patients all had aneurysms associated with their dissection, of which all except one were asymptomatic, and had an average maximum aortic diameter of 60.5 6 11.6 mm. Fifty-one patients (25.5%) had undergone a prior aortic repair, and 80 (40%) required surgical modification for adequate landing zone. Forty-seven (22.6%) iliac conduits were required for adequate access, 41 of which were performed before TEVAR.
Other additional procedures at the time of TEVAR included 13 carotid stents, of which five were placed because of unintended TEVAR impingement on the left common carotid artery (three in patients with prior left carotid-to-left subclavian artery [LCSCA] bypasses), and eight were associated with a proximal scallop to the left common carotid artery. Of the device data available, they were all balloon-expandable stents. One left middle cerebral artery stroke occurred in a patient who underwent TEVAR with a proximal scallop and left common carotid stent, and prior LCSCA bypass. The stroke was thought to occur as a result of thrombus propagation after left subclavian artery coil embolization.
There were also 5 celiac stents (all associated with distal scallop to celiac), 2 renal stents (both to treat renal artery stenosis), and 4 iliac stents (1 each to treat impingement of mesenteric bypass, iliac aneurysm, bleeding, and dissection), and 1 abdominal endovascular aortic repair to treat a concomitant AAA. Also performed at the time of TEVAR were 23 subclavian and one hypogastric artery embolizations.
Mortality. Operative mortality occurred in 13 patients (6.5%), with 129 deaths (64.5%) during follow-up (Table III) . Survival estimates from all-cause mortality for all TEVAR patients at 1, 3, 5, and 9 years were 85.8%, 71.5%, 55.6%, and 31.4%, respectively (Fig 2, A) . There were 17 aneurysm-related deaths at an average of 0.9 years One patient with an aortobronchial fistula was included in the total median (IQR). 
Unknown 0 (0) 10 (9) 10 (7) (median, 0.05; IQR, 0.04-0.11 years), 12 of which were in the first 30 days. Patients treated for TAA had a significantly higher overall mortality than those treated for chronic dissection (P ¼ .009; Fig 2, B) . (Fig 2, A) . Sixteen of the aneurysm-related deaths were in TAA patients, and one was in a chronic dissection patient.
Ruptures. Six postoperative ruptures (3.0%) occurred, five of which resulted in death and one that was treated as an emergency, without further issue. Time to rupture from the initial surgery was a mean of 5.3 6 3.9 years (range, 25 days-10 years). Two ruptures were thought to be associated with type I endoleaks, three caused by component separation, and 1 from barb fractures associated with proximal aneurysm enlargement without endoleak or migration. Reintervention for these issues was declined by the patient or contraindicated in four patients, and one patient with component separation ruptured before the scheduled reintervention. One patient presented with rupture and component separation after an unremarkable CT scan 5 months earlier and was treated with a thoracic graft, without further complication.
Secondary interventions.
A total of 67 secondary interventions were performed in 50 patients (25% ; Table IV) . Freedom from secondary intervention was 82.9%, 78.3%, 75.5%, and 64.0% at 1, 3, 5, and 9 years, respectively (Fig 3) . Procedure-related complications from the primary TEVAR operation resulted in 20 interventions performed in 17 patients (Table IV) Table V ). Freedom from any endoleak was 77.8%, 77.2%, 72.2%, and 62.3% at 1, 2, 5, and 9 years, respectively (Fig 4) . A type I endoleak occurred in 20 patients (11 primary, 9 secondary), type II in 32 (14 primary, 18 secondary), type III in 6 (2 primary, 4 secondary), type IV in 0, and unknown in (1 primary, 2 secondary). A univariate analysis evaluating patient, aortic, and procedural variables found no significant differences between patients who did and did not develop endoleaks (P > .05). There was also no significant difference in the rate of endoleak (29.2% vs 26.7%) or secondary intervention (16.7% vs 26.1%) when patients with a scallop and those with a standard TEVAR device were compared.
Indications for treatment of endoleaks included the presence of a type I or type III endoleak as well as type II endoleaks in the setting aneurysmal growth. 18 Reinterventions were required in 13 patients with a type I endoleak, of which six patients were treated endovascularly, including proximal or distal extensions; however, seven patients ultimately required open repair. Of the four patients with type I endoleaks that were not treated, two endoleaks resolved by the next follow-up CT scan, and two patients died of unrelated causes before planned open repair. Two patients with type III endoleaks were successfully treated with endovascular extensions to correct component separation. Of the four patients who were not treated, three were offered treatment but died before the intervention or did not follow-up, and one was managed medically due to severe comorbidities and lack of suitable endovascular options. Only one patient required intervention of a type II endoleak, which was treated with coil embolization at 5.6 years.
Aneurysm sac change. The aneurysm sac size was stable or decreased over time in most patients (Table VI) . Aneurysm growth (>5 mm) was noted in 16 patients, with the first point of growth noted at a median 3.3 years (IQR, 2.0-5.2 years). Aneurysm growth was more common in patients with a type I endoleak (9.4% vs 48.8%; P < .001) and in those with migration (8.9% vs 31.2%; P < .05). Growth was thought to be associated with a type I endoleak in 6 patients, a type III endoleak in 2 patients, device migration caused by disease progression in 1, and barb or strut fracture, or both, in 2 additional patients. One patient went into cardiac arrest and died 18 days postoperatively after a retrograde dissection with associated sac growth. Eight patients with sac growth underwent reintervention, five of whom were treated with endovascular interventions, and three with persistent proximal landing zone issues were treated with reverse frozen elephant trunk or open arch repair. Three other patients were noted to have growth without an identifiable cause or visible endoleak, and two of these patients stabilized without intervention.
Device integrity and migration. Component separation developed in five patients at an average of 3.8 6 0.6 years. Intercomponent movement developed in one patient who was treated prophylactically with a stent graft; however, type III endoleaks developed in the four other patients. Two of these were successfully treated with stent grafts, but the other two did not return for follow-up or died before repeat intervention.
Barb fractures were noted in 11 patients and stent fractures in three patients at an average of 3.9 6 1.6 years. Migration, endoleak, or other clinical event thought to be attributed to the device fracture did not develop in 11 of these 14 patients, and therefore, no related reinterventions were performed. A stent fracture developed in one patient at 3.4 years and in another with two barb fractures at 5.2 and 7.6 years, which were attributed to progressive proximal/distal aneurysmal growth. One patient was offered intervention but declined and died of rupture of the aneurysm proximal to the treated aorta. No adverse event was thought to be attributed to a barb or stent fracture or related to barbs perforating the aorta.
Stent graft migration occurred in 22 patients at an average of 3.2 6 1.7 years. Indications for intervention were the development of a type I or type III endoleak, aneurysmal growth, or prophylactic intervention in patients with >10 mm in cranial or caudal direction. Reinterventions were performed in 9 of these patients, 8 were treated with additional TEVAR devices, 1 of which also required a reverse frozen elephant trunk, and 1 patient with TAAA underwent a fenestrated endovascular repair. Endoleaks were found in three patients, and one ruptured before repair. Migration was most commonly caused by progressive aneurysmal degeneration or growth.
Freedom from a composite outcome end point, defined as freedom from secondary intervention, stent migration, endoleak, aneurysm growth, or spinal cord injury, is shown in Fig 5. Freedom from this composite end point was 68.3%, 57.9%, 50%, and 43.1% at 30 days, 1, 3, and 5 years, respectively. The rate of spinal cord ischemia was 4% (8 patients), all of which occurred within the first 30 days after surgery. The perioperative stroke rate was 3.5% (7 patients) in this cohort.
DISCUSSION
Several trials have provided strong evidence that TEVAR has significant early benefit compared with open surgical repair. 5, 11, 12 This study extends these findings by providing evidence that TEVAR continues to provide long-term protection against aneurysm-related death and rupture. Aneurysm-related survival in this study is excellent, with 91.7% survival at 5 years, similar to that seen in multicenter TEVAR trials, and is stable out to 10 years. 5, 12 This low rate of aneurysm-related events must be taken in context of a patient population with a very high overall mortality. Unadjusted survival rates at 5 and 9 years are 55.6% and 31.4%, similar to 5-year (4) 11 ( (5) 14 (8) 15 (5) 16 (4) 19 (4) Multiple
survival of 63% to 68% noted for both open and TEVAR patients in the literature. 5, 10, 12, 13 In contrast to other trials, many of the patients in this study were at high risk for repair not only medically but also anatomically: >40% of these patients required surgical modification, including elephant trunks, LCSCA bypass, or mesenteric bypasses, for an adequate landing zone or to address tortuous morphology, >25% had undergone prior aneurysm repair, and w25% required iliac or aortic conduits to handle challenging access. Although the use of these adjunct procedures is significantly lower in general TEVAR use, it highlights the importance of preoperative planning, particularly with regards to device placement and fixation zones. We feel strongly that preoperative planning with threedimensional imaging is very helpful to assess the neck shape, presence of calcification or thrombus, and relationship to branch vessels of the proximal and distal landing zones. Several of the cases of migration could be attributed to landing the TEVAR device into unhealthy aorta. This often results in secondary interventions that are often complicated and may require branched/fenestrated devices or conversion to an open repair to seal into healthy aorta.
Migration was rare in this trial; however, several cases were associated with progressive aneurysmal degeneration proximally or distally. Barb separation was noted in 11 patients, however, was thought to be associated with migration in one patient and rarely required secondary intervention. Several of these events were also noted in the TX2 trial and thought to be contributed by suboptimal wall apposition. 6 Three migrations occurred in the 23 ; nonetheless, encouraging results from this group are that even in a higher-risk and more anatomically complex population, the risk of new endoleaks, device-related complication, and secondary interventions remains low.
In the treatment of patients with aortic aneurysms, TEVAR or open repair does not resolve the underlying disease. Even without device failure or complications, adjacent or even disparate segments of aorta may continue to degenerate with further dilation, elongation, or increased tortuosity. TEVAR is highly successful at treating the aortic pathology and preventing long-term rupture; however, the trade-off is the necessity for longterm imaging follow-up and timely intervention to address device-related issues or progression of aortic aneurysmal disease.
Results from this single-center experience provide some of the longest prospectively collected data on patients who were treated with Zenith TX1 or TX2 TEVAR devices and an opportunity to gain insight into the longterm outcomes and potential late complications of these devices. A major strength of this report is the high patient accountability, particularly with regards to standardized imaging verification to ensure accurate reporting of device events and aneurysmal changes. These strengths can also be viewed as limitations. It is important to note that this experience represents an early experience with first-generation Zenith TX1 and TX2 TEVAR devices, and to some degree, these results likely include a learning curve. As a large referral center with extensive experience in complex aortic and endovascular procedures, these patients and the operators' clinical experience may not be representative, although they do provide insight into a subset of challenging patients that even so have low aneurysm-related events longterm.
Another limitation is that this study only evaluates a single device over a 10-year period, during which several device-related changes were made and thus may affect the rate of events and outcomes seen over time. A large number of variables were collected prospectively; however, the length of aorta covered was not measured and, therefore, was not included in our analysis.
CONCLUSIONS
TEVAR with the Zenith TX1 and TX2 is durable and associated with high long-term aneurysm-related survival and low risk of rupture. Long-term imaging follow-up remains critical to identify endoleaks or rare device durability issues, most of which can be monitored or managed with endovascular therapies. Even with these impressive advances in endovascular therapy, the longterm survival of these patients is poor. The limiting factor to evaluating the long-term durability and late rupture risk in these patients remains their high rate of mortality from underlying comorbidities in this high risk population.
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